SCHEMBL30325699

SCHEMBL30325699

C=CC(=O)Nc1ccc(-c2c(-c3ccc(Oc4ncccn4)c(OC)c3)c3c(N)ncc(C#N)c3n2C)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 3/20 0.40
▸ FGFR1 P11362 2/20 0.40
▸ FGFR2 P21802 2/20 0.40
▸ FGFR3 P22607 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ GAK O14976 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ BTK Q06187 2/20 0.37
▸ EGFR P00533 6/20 0.36
▸ ERBB2 P04626 1/20 0.36
▸ TBK1 Q9UHD2 1/20 0.36
▸ CCNK O75909 1/20 0.35
▸ CDK12 Q9NYV4 1/20 0.35
▸ CTSC P53634 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ ITK Q08881 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29265805 1.00 FGFR4 (0.40) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL31213950 0.92 FGFR4 (0.49) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL29265947 0.91 FGFR4 (0.49) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL30325827 0.91 FGFR4 (0.49) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL31213975 0.89 FGFR4 (0.40) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL29265717 0.89 BTK (0.40) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL30326041 0.89 BTK (0.40) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL29265917 0.86 TBK1 (0.45) FGFR4FGFR1FGFR2FGFR3GAK
SCHEMBL30325720 0.86 TBK1 (0.45) FGFR4FGFR1FGFR2FGFR3GAK
SCHEMBL31213960 0.85 FGFR4 (0.46) FGFR4FGFR1FGFR2FGFR3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 FGFR4 3/4885FGFR1 1/4885FGFR2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback